Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 360

1.

Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.

Ho JC, Chang AM, Yan BP, Yu CM, Lam YY, Lee VW.

Clin Cardiol. 2012 Dec;35(12):E40-5. doi: 10.1002/clc.22069. Epub 2012 Oct 25.

2.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.

Chang AM, Ho JC, Yan BP, Yu CM, Lam YY, Lee VW.

Clin Cardiol. 2013 May;36(5):280-5. doi: 10.1002/clc.22112. Epub 2013 Mar 14.

3.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators.

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
4.

Continuation of dabigatran therapy in "real-world" practice in Hong Kong.

Ho MH, Ho CW, Cheung E, Chan PH, Hai JJ, Chan KH, Chan EW, Leung GK, Tse HF, Siu CW.

PLoS One. 2014 Aug 1;9(8):e101245. doi: 10.1371/journal.pone.0101245. eCollection 2014.

5.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

6.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23.

PMID:
23615428
7.

Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.

Salazar CA, del Aguila D, Cordova EG.

Cochrane Database Syst Rev. 2014 Mar 27;(3):CD009893. doi: 10.1002/14651858.CD009893.pub2. Review.

PMID:
24677203
8.

Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.

Bergh M, Marais CA, Miller-Jansön H, Salie F, Stander MP.

S Afr Med J. 2013 Feb 15;103(4):241-5. doi: 10.7196/samj.6471.

PMID:
23547700
9.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
10.

Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.

Berger R, Salhanick SD, Chase M, Ganetsky M.

Ann Emerg Med. 2013 Apr;61(4):475-9. doi: 10.1016/j.annemergmed.2013.02.008.

PMID:
23522810
11.

Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.

Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G, Froehlich JB, Goldhaber SZ.

Am J Cardiol. 2013 Aug 1;112(3):387-9. doi: 10.1016/j.amjcard.2013.03.046. Epub 2013 May 3.

PMID:
23647794
12.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
13.

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.

Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L.

Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.

14.

Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.

Ali A, Bailey C, Abdelhafiz AH.

Age Ageing. 2012 Sep;41(5):681-4. doi: 10.1093/ageing/afs017. Epub 2012 Feb 28.

PMID:
22378612
15.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hammès F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

16.

Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.

[No authors listed]

Prescrire Int. 2012 Feb;21(124):33-6. Review.

PMID:
22413715
17.

Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

Meyer Dos Santos S, Harder S.

Drug Saf. 2014 May;37(5):295-307. doi: 10.1007/s40264-014-0151-1. Review.

PMID:
24683059
18.

Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.

Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators.

Eur J Heart Fail. 2013 Sep;15(9):1053-61. doi: 10.1093/eurjhf/hft111. Epub 2013 Jul 9.

19.

Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.

Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J.

Int J Cardiol. 2013 Oct 3;168(3):2540-7. doi: 10.1016/j.ijcard.2013.03.059. Epub 2013 May 8.

PMID:
23664436
20.

Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.

Waks JW, Zimetbaum PJ.

Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1461-71. doi: 10.1586/14779072.2013.849572. Epub 2013 Oct 23.

PMID:
24147516

Supplemental Content

Support Center